|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910781003703321 |
|
|
Autore |
Hanson Sarah |
|
|
Titolo |
CNS clinical trials [[electronic resource] ] : suicidality and data collection : workshop summary / / Sarah Hanson, Miriam Davis, and Bruce Altevogt ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Washington, D.C., : National Academies Press, 2010 |
|
|
|
|
|
|
|
ISBN |
|
0-309-18648-X |
1-282-97591-9 |
9786612975912 |
0-309-14884-7 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Altri autori (Persone) |
|
DavisMiriam |
AltevogtBruce M |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Suicide - Risk factors |
Suicide - Prevention |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Bibliographic Level Mode of Issuance: Monograph |
|
|
|
|
|
|
Nota di contenuto |
|
Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
"The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description. |
|
|
|
|
|
|
|